SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Why the future of marijuana legalization remains hazy despite high public support 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Shares of women’s healthcare company Organon & Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following reports that India-based Sun Pharmaceutical Industries Ltd. (NSE: SUN) is preparing a $13 billion acquisition offer. The news sparked strong investor interest, pushing Organon stock up as much as 8% to above $9.20 per share.
The surge comes despite Organon’s relatively modest market capitalization of $2.2 billion at the close of regular trading, highlighting the significant premium implied by the reported deal. According to sources cited by The Economic Times, Sun Pharma is planning to submit a binding all-cash offer, with financing reportedly backed by major global banks including JPMorgan, MUFG, and Citi.
The potential acquisition signals Sun Pharma’s strategic push to expand its footprint in the fast-growing women’s healthcare segment. Organon, a spin-off from Merck, specializes in reproductive health, biosimilars, and established medicines, making it an attractive target for global pharmaceutical companies seeking diversification and innovation in healthcare portfolios.
Reports also indicate that Sun Pharma intends to fully integrate Organon into its existing operations rather than issuing shares to Organon investors. This move suggests a long-term commitment to leveraging Organon’s capabilities, particularly its U.S.-based manufacturing infrastructure, which is considered a valuable asset in the pharmaceutical industry.
The deal has reportedly drawn competition from Germany’s Gruenthal, underscoring the increasing demand for companies focused on women’s health solutions. As pharmaceutical giants race to strengthen their pipelines and global reach, acquisitions like this could reshape the competitive landscape.
Investors and analysts are closely watching developments, as confirmation of the deal could significantly impact both companies’ valuations and the broader healthcare sector. The potential buyout highlights the growing importance of women’s health in global pharma strategies, while reinforcing Organon’s position as a key player in this specialized market.
